The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany

INTRODUCTION: Empagliflozin reduced morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) in clinical trials. A registry study was undertaken to describe evolution of patient characteristics and assess the real-world effectiveness/safety of empagliflozin. RESEARCH DESIGN AND METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Bramlage, Peter, Tittel, Sascha R, Wagner, Christian, König, Kerstin, Raddatz, Dirk, Weber-Lauffer, Rosmarie, Erath, Diether, Hilgenberg, Jost, Spies, Carsten, Danne, Thomas, Gabler, Maximilian, Foersch, Johannes, Ley, Ludwin, Seufert, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388887/
https://www.ncbi.nlm.nih.gov/pubmed/32719080
http://dx.doi.org/10.1136/bmjdrc-2020-001486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388887/
https://www.ncbi.nlm.nih.gov/pubmed/32719080
http://dx.doi.org/10.1136/bmjdrc-2020-001486

Ejemplares similares